Understanding heart inflammation after COVID-19 vaccination
Official title: Comprehensive genomic and inflammatory profiling of vaccine-associated myocarditis
Funded at Icahn School of Medicine at Mount Sinai · NIH-10734071 · Data updated 2026-11-12
This study is looking at how some people might be more likely to develop myocarditis, a rare heart condition, after getting a COVID-19 vaccine, and it’s inviting kids and adults aged 5 and up who have experienced this condition to help by sharing their genetic information so we can better understand and protect those at risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 3, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $211,250 |
| NIH project number | 5R21AI174216-02 |
| Project ID | NIH-10734071 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals aged 5 years and older who have experienced myocarditis following COVID-19 vaccination.
✕Less likely to help
Patients who have not received a COVID-19 vaccine or those without a history of myocarditis will likely not benefit from this research.
What this research studies
This research investigates the rare but significant heart condition known as myocarditis that can occur after COVID-19 vaccination. By analyzing genetic factors and immune responses, the study aims to identify individuals who may be at higher risk for developing this condition. Participants aged 5 years and older with vaccine-associated myocarditis will undergo genetic testing to uncover potential risk factors. The goal is to improve vaccination strategies and minimize risks for susceptible individuals.
Why it matters
Potential benefit: If successful, this research could lead to better identification of individuals at risk for vaccine-associated myocarditis, allowing for safer vaccination practices.
How similar studies have gone: While myocarditis is a known complication, this specific genomic approach to understanding vaccine-associated myocarditis is novel and has not been extensively tested in prior research.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Kontorovich, Amy R. — Icahn School of Medicine at Mount Sinai
- Study coordinator: Kontorovich, Amy R.
Related research
Other NIH-funded projects on the same topics.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Viral tricks that disrupt heart cell connections in myocarditis
This grant looks at how a common cold virus (adenovirus) may mess with the heart’s electrical signals and could lead to dangerous arrhythmias in people with myocarditis.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.